Security Snapshot

Arbutus Biopharma Corp - Common Shares, without par value (ABUS) Institutional Ownership

CUSIP: 03879J100

13F Institutional Holders and Ownership History from Q2 2015 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

173

Shares (Excl. Options)

122,028,178

Price

$4.81

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Shares, without par value
Symbol
ABUS on Nasdaq
Shares outstanding
197,428,263
Price per share
$4.30
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
122,028,178
Total reported value
$586,934,773
% of total 13F portfolios
0%
Share change
+3,801,262
Value change
+$19,507,202
Number of holders
173
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • ABUS - Arbutus Biopharma Corp - Common Shares, without par value is tracked under CUSIP 03879J100.
  • 173 institutions reported positions in Q4 2025.
  • 4 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 173 to 59 between Q4 2025 and Q1 2026.
  • Reported value moved from $586,934,773 to $76,224,039.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 173 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 03879J100?
CUSIP 03879J100 identifies ABUS - Arbutus Biopharma Corp - Common Shares, without par value in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Roivant Sciences Ltd. 20% 0% $127,808,150 38,847,462 0% Roivant Sciences Ltd. 21 Feb 2025
MORGAN STANLEY 14% +19% $122,814,997 +$20,788,104 25,910,337 +20% Morgan Stanley 31 Dec 2025
Whitefort Capital Management, LP 8% -1.2% $71,074,174 15,794,261 0% Whitefort Capital Master Fund, LP 24 Apr 2026
Two Seas Capital LP 6.5% +22% $59,672,609 +$10,171,286 12,589,158 +21% Two Seas Capital LP 31 Dec 2025

As of 31 Dec 2025, 173 institutional investors reported holding 122,028,178 shares of Arbutus Biopharma Corp - Common Shares, without par value (ABUS). This represents 62% of the company’s total 197,428,263 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) together control 57% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
MORGAN STANLEY 14% 26,702,776 +9.2% 0.01% $128,440,353
Whitefort Capital Management, LP 6.8% 13,343,228 0% 19% $64,180,927
BlackRock, Inc. 6.6% 13,052,861 +3% 0% $62,784,261
Two Seas Capital LP 6.4% 12,589,158 +15% 3.5% $60,553,850
VANGUARD GROUP INC 4.7% 9,242,437 +2.8% 0% $44,456,122
STATE STREET CORP 3% 5,908,211 +44% 0% $28,418,495
ADAR1 Capital Management, LLC 2.7% 5,415,109 +87% 1.9% $26,046,674
ADAGE CAPITAL PARTNERS GP, L.L.C. 2.2% 4,339,941 -13% 0.03% $20,875,116
GEODE CAPITAL MANAGEMENT, LLC 1.9% 3,677,307 +0.3% 0% $17,691,051
Woodline Partners LP 1.1% 2,186,553 +0.97% 0.04% $10,517,320
BlackBarn Capital Partners LP 0.94% 1,850,000 -7.5% 3.2% $8,898,500
BANK OF AMERICA CORP /DE/ 0.93% 1,832,704 +26% 0% $8,815,305
Rubric Capital Management LP 0.8% 1,575,376 0% 0.09% $7,577,559
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.79% 1,562,265 +23% 0% $7,514,495
OSAIC HOLDINGS, INC. 0.68% 1,348,224 +0.73% 0.01% $6,484,957
NORTHERN TRUST CORP 0.63% 1,236,689 -4.1% 0% $5,948,475
STEMPOINT CAPITAL LP 0.5% 986,751 +380% 0.81% $4,746,272
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 0.45% 890,898 0% $4,285,220
Rangeley Capital, LLC 0.43% 840,000 0% 3.5% $4,040,400
BANK OF MONTREAL /CAN/ 0.39% 766,656 +0.18% 0% $3,687,615
GOLDMAN SACHS GROUP INC 0.37% 738,580 -66% 0% $3,552,570
Hudson Bay Capital Management LP 0.34% 675,000 -16% 0.02% $3,246,750
CITIGROUP INC 0.31% 611,149 +209% 0% $2,939,626
Quinn Opportunity Partners LLC 0.26% 514,513 0% 0.11% $2,474,808
Western Standard LLC 0.26% 507,853 0% 1.1% $2,442,773

Institutional Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 16,938,857 $76,224,039 +$20,686,443 $4.50 59
2025 Q4 122,028,178 $586,934,773 +$19,507,202 $4.81 173
2025 Q3 118,168,575 $536,370,600 +$2,487,933 $4.54 166
2025 Q2 118,112,086 $364,964,865 +$19,645,984 $3.09 162
2025 Q1 111,778,063 $390,115,968 +$29,488,807 $3.49 167
2024 Q4 104,075,822 $340,339,884 +$3,767,856 $3.27 153
2024 Q3 101,100,254 $389,229,670 +$15,557,626 $3.85 143
2024 Q2 96,687,257 $298,333,597 +$40,873,896 $3.09 129
2024 Q1 83,370,717 $215,132,214 +$11,550,835 $2.58 118
2023 Q4 78,913,089 $197,297,266 +$10,900,831 $2.50 110
2023 Q3 70,841,695 $143,815,507 +$8,057,833 $2.03 96
2023 Q2 66,235,432 $152,407,843 +$7,387,882 $2.30 109
2023 Q1 62,470,799 $189,264,221 +$26,478,755 $3.03 120
2022 Q4 54,227,682 $126,382,359 +$17,821,528 $2.33 110
2022 Q3 46,620,587 $89,144,270 -$921,936 $1.91 121
2022 Q2 35,268 $93,574 -$3,027,847 $2.18 11
2022 Q1 43,886,769 $130,608,351 +$4,239,945 $2.98 111
2021 Q4 39,679,851 $154,349,574 +$14,066,593 $3.89 114
2021 Q3 34,872,896 $149,655,492 +$26,301,612 $4.29 96
2021 Q2 28,908,795 $87,633,862 +$7,803,555 $3.03 83
2021 Q1 25,991,001 $86,467,063 +$11,894,875 $3.33 88
2020 Q4 21,915,953 $77,813,914 -$4,704,362 $3.55 72
2020 Q3 24,142,348 $75,528,504 +$7,771,699 $3.13 60
2020 Q2 26,122,191 $47,560,467 +$748,885 $1.82 46
2020 Q1 26,281,827 $26,537,879 -$13,148,563 $1.01 44
2019 Q4 24,261,532 $67,445,419 +$11,932,336 $2.78 51
2019 Q3 19,461,984 $29,679,262 -$3,274,294 $1.52 44
2019 Q2 21,113,616 $43,982,113 -$11,240,138 $2.08 56
2019 Q1 24,075,098 $86,186,166 -$440,804 $3.58 64
2018 Q4 24,175,022 $92,584,064 -$11,019,460 $3.83 65
2018 Q3 24,015,267 $227,302,706 +$34,721,438 $9.45 86
2018 Q2 20,448,527 $149,271,310 +$19,689,424 $7.30 67
2018 Q1 18,377,666 $91,890,575 -$79,594,386 $5.00 45
2017 Q4 34,211,265 $172,779,991 +$12,813,644 $5.05 50
2017 Q3 31,250,927 $193,761,084 -$33,550,517 $6.20 51
2017 Q2 36,887,584 $132,791,952 +$3,194,137 $3.60 45
2017 Q1 36,322,621 $118,047,315 +$819,274 $3.25 50
2016 Q4 36,190,341 $88,841,049 +$4,195,879 $2.45 52
2016 Q3 33,443,140 $115,042,069 +$54,657,856 $3.44 46
2016 Q2 17,549,536 $61,069,070 -$709,869 $3.48 47
2016 Q1 17,711,768 $73,144,106 -$3,356,008 $4.13 47
2015 Q4 18,370,048 $81,745,000 -$100,433,658 $4.45 47
2015 Q3 34,854,473 $212,262,000 +$210,998,423 $6.09 52
2015 Q2 207,417 $2,460,000 +$2,460,000 $11.86 1
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .